ICATIBANT Pharmacologic Class Indexing
- Class set ID
- a62f5b1e-5193-4ef6-88ef-41c3de71cb7c
- Version
- 3
- Effective date
- 20180813
- Type
- Indexing - Pharmacologic Class
Mapped DailyMed Labels#
Label, Manufacturer, Effective table| Label | Manufacturer | Effective | SPL version |
|---|
| These highlights do not include all the information needed to use FIRAZYR ® (icatibant) safely and effectively. See full prescribing information for FIRAZYR. FIRAZYR (icatibant) Injection, for subcutaneous use Initial U.S. Approval: 2011 | Takeda Pharmaceuticals America, Inc. | 20250707 | 19 |
| These highlights do not include all the information needed to use ICATIBANT INJECTION safely and effectively. See full prescribing information for ICATIBANT INJECTION. ICATIBANT injection, for subcutaneous use Initial U.S. Approval: 2011 | Alembic Pharmaceuticals Inc. | Alembic Pharmaceuticals Limited (F3) | 20250701 | 8 |
| These highlights do not include all the information needed to use ICATIBANT INJECTION safely and effectively. See full prescribing information for ICATIBANT INJECTION. ICATIBANT injection, for subcutaneous use Initial U.S. Approval: 2011 | Alembic Pharmaceuticals Limited | Alembic Pharmaceuticals Limited (F3) | 20250627 | 1 |
| These highlights do not include all the information needed to use ICATIBANT INJECTION safely and effectively. See full prescribing information for ICATIBANT INJECTION. ICATIBANT injection, for subcutaneous use Initial U.S. Approval: 2011 | Hikma Pharmaceuticals USA Inc. | 20240425 | 19 |
| These highlights do not include all the information needed to use ICATIBANT INJECTION safely and effectively. See full prescribing information for ICATIBANT INJECTION. ICATIBANT injection, for subcutaneous use Initial U.S. Approval: 2011 | Eugia US LLC | Auro Peptides Limited | Eugia Pharma Specialities Limited | 20240402 | 2 |
| These highlights do not include all the information needed to use ICATIBANT INJECTION safely and effectively. See full prescribing information for ICATIBANT INJECTION. ICATIBANT injection, for subcutaneous use Initial U.S. Approval: 2011 | Cipla USA Inc. | GLAND PHARMA LIMITED | BCN Peptides SA | 20240216 | 6 |
| These highlights do not include all the information needed to use SAJAZIR™ (icatibant) safely and effectively. See full prescribing information for SAJAZIR™. SAJAZIR™ (icatibant) injection, for subcutaneous use Initial U.S. Approval: 2011 | Cycle Pharmaceuticals Ltd-Uk | Cipla USA Inc. | GLAND PHARMA LIMITED | 20240216 | 5 |
| These highlights do not include all the information needed to use ICATIBANT INJECTION safely and effectively. See full prescribing information for ICATIBANT INJECTION . ICATIBANT injection, for subcutaneous use Initial U.S. Approval: 2011 | Teva Pharmaceuticals USA, Inc. | 20240215 | 9 |
| These highlights do not include all the information needed to use ICATIBANT INJECTION safely and effectively. See full prescribing information for ICATIBANT INJECTION. ICATIBANT injection, for subcutaneous use Initial U.S. Approval: 2011 | Fresenius Kabi USA, LLC | Fresenius Kabi Austria | 20231108 | 4 |